

Steve E Kalloger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7818929/publications.pdf>

Version: 2024-02-01

87
papers

9,847
citations

61984

43
h-index

49909

87
g-index

87
all docs

87
docs citations

87
times ranked

13857
citing authors

#	ARTICLE	IF	CITATIONS
1	Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In?. <i>Clinical Cancer Research</i> , 2021, 27, 246-254.	7.0	16
2	Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics. <i>Clinical Cancer Research</i> , 2021, 27, 150-157.	7.0	24
3	Reproducibility of tumor budding assessment in pancreatic cancer based on a multicenter interobserver study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 719-726.	2.8	3
4	Stroma vs epithelium-enhanced prognostics through histologic stratification in pancreatic ductal adenocarcinoma. <i>International Journal of Cancer</i> , 2021, 148, 481-491.	5.1	7
5	Modelling hereditary diffuse gastric cancer initiation using transgenic mouse-derived gastric organoids and single-cell sequencing. <i>Journal of Pathology</i> , 2021, 254, 254-264.	4.5	11
6	Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma. <i>Cancer Medicine</i> , 2021, 10, 1155-1165.	2.8	9
7	Advancing the Care of Pancreatic Cancer Patients: Moving Beyond Just Tumour Tissue. <i>Biomarker Insights</i> , 2021, 16, 117727192110498.	2.5	1
8	Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms. <i>Cell Reports</i> , 2021, 37, 109817.	6.4	14
9	Altered Gene Expression along the Glycolysis-Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 135-146.	7.0	121
10	Genetic testing for hereditary cancer syndromes: patient recommendations for improved risk communication. <i>Health Expectations</i> , 2020, 23, 884-892.	2.6	15
11	Loss of switch/sucrose non-fermenting complex protein expression in undifferentiated gastrointestinal and pancreatic carcinomas. <i>Histopathology</i> , 2020, 77, 46-54.	2.9	39
12	Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1889-1897.	4.1	10
13	Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening. <i>Cancer Medicine</i> , 2020, 9, 4004-4013.	2.8	25
14	Mitochondrial DNA somatic mutation burden and heteroplasmy are associated with chronological age, smoking, and HIV infection. <i>Aging Cell</i> , 2019, 18, e13018.	6.7	27
15	Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia. <i>Gastroenterology</i> , 2019, 157, 823-837.	1.3	153
16	Dynamics of leukocyte telomere length in pregnant women living with HIV, and HIV-negative pregnant women: A longitudinal observational study. <i>PLoS ONE</i> , 2019, 14, e0212273.	2.5	7
17	Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002329.	1.2	30
18	Temporal Dynamics of Genomic Alterations in a BRCA1 Germline-Mutated Pancreatic Cancer With Low Genomic Instability Burden but Exceptional Response to Fluorouracil, Oxaliplatin, Leucovorin, and Irinotecan. <i>JCO Precision Oncology</i> , 2018, 2, 1-8.	3.0	1

#	ARTICLE	IF	CITATIONS
19	Increased Cancer Risk in Younger Patients with Thyroid Nodules Diagnosed as Atypia of Undetermined Significance. <i>Cureus</i> , 2018, 10, e2348.	0.5	4
20	siRNA Library Screening Identifies a Druggable Immune-Signature Driving Esophageal Adenocarcinoma Cell Growth. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018, 5, 569-590.	4.5	17
21	A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 179-190.	3.0	12
22	Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. <i>BMC Cancer</i> , 2017, 17, 618.	2.6	42
23	Classification of Extraovarian Implants in Patients With Ovarian Serous Borderline Tumors (Tumors) Tj ETQq1 1 0.784314 rgBT /Overl 2016, 40, 1155-1164.	3.7	30
24	Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. <i>Nature Genetics</i> , 2016, 48, 758-767.	21.4	287
25	Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer. <i>Journal of Histochemistry and Cytochemistry</i> , 2016, 64, 587-600.	2.5	30
26	Immunophenotyping of ampullary carcinomata allows for stratification of treatment specific subgroups. <i>Journal of Clinical Pathology</i> , 2016, 69, 431-439.	2.0	19
27	Single-Patient Molecular Testing with NanoString nCounter Data Using a Reference-Based Strategy for Batch Effect Correction. <i>PLoS ONE</i> , 2016, 11, e0153844.	2.5	17
28	Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell and patient-derived tumor organoids. <i>Nature Medicine</i> , 2015, 21, 1364-1371.	30.7	591
29	Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma. <i>Modern Pathology</i> , 2015, 28, 1383-1389.	5.5	51
30	Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. <i>Oncotarget</i> , 2015, 6, 39088-39097.	1.8	67
31	HSulf-1 deficiency dictates a metabolic reprogramming of glycolysis and TCA cycle in ovarian cancer. <i>Oncotarget</i> , 2015, 6, 33705-33719.	1.8	28
32	ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. <i>Modern Pathology</i> , 2014, 27, 255-261.	5.5	110
33	HER2/neu Testing in Gastric Cancer by Immunohistochemistry: Assessment of Interlaboratory Variation. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 1495-1502.	2.5	31
34	Current Morphologic Criteria Perform Poorly in Identifying Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome-associated Uterine Leiomyomas. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 560-567.	1.4	25
35	ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts. <i>Human Pathology</i> , 2014, 45, 1258-1268.	2.0	34
36	Expression of Matrix Metalloproteinase-1 in Alveolar Macrophages, Type II Pneumocytes, and Airways in Smokers: Relationship to Lung Function and Emphysema. <i>Lung</i> , 2014, 192, 467-472.	3.3	5

#	ARTICLE	IF	CITATIONS
37	Determinants of Quality of Life in Ovarian Cancer Survivors: A Pilot Study. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2014, 36, 708-715.	0.7	30
38	Reproducibility of histological cell type in high-grade endometrial carcinoma. <i>Modern Pathology</i> , 2013, 26, 1594-1604.	5.5	167
39	The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors. <i>Modern Pathology</i> , 2013, 26, 1255-1263.	5.5	52
40	Specimen Quality Evaluation in Canadian Biobanks Participating in the COEUR Repository. <i>Biopreservation and Biobanking</i> , 2013, 11, 83-93.	1.0	35
41	Quantification of ER/PR expression in ovarian low-grade serous carcinoma. <i>Gynecologic Oncology</i> , 2013, 128, 371-376.	1.4	63
42	Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells. <i>Cell Cycle</i> , 2013, 12, 1433-1449.	2.6	78
43	Stage II to IV Low-grade Serous Carcinoma of the Ovary Is Associated With a Poor Prognosis. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 529-535.	1.4	34
44	Biomarker-Based Ovarian Carcinoma Typing: A Histologic Investigation in the Ovarian Tumor Tissue Analysis Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1677-1686.	2.5	70
45	Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (<sc>COSP</sc>) is a reliable high-throughput tool for case review. <i>Histopathology</i> , 2013, 63, 704-712.	2.9	5
46	Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research. <i>PLoS ONE</i> , 2013, 8, e72162.	2.5	200
47	Markers of T Cell Infiltration and Function Associate with Favorable Outcome in Vascularized High-Grade Serous Ovarian Carcinoma. <i>PLoS ONE</i> , 2013, 8, e82406.	2.5	22
48	BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. <i>Modern Pathology</i> , 2012, 25, 740-750.	5.5	151
49	Architectural Patterns of Ovarian/Pelvic High-grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2012, 31, 397-404.	1.4	25
50	Transitional Cell Carcinoma of the Ovary is Related to High-grade Serous Carcinoma and is Distinct From Malignant Brenner Tumor. <i>International Journal of Gynecological Pathology</i> , 2012, 31, 499-506.	1.4	65
51	Recurrent Somatic <i>DICER1</i> Mutations in Nonepithelial Ovarian Cancers. <i>New England Journal of Medicine</i> , 2012, 366, 234-242.	27.0	401
52	Use of Mismatch Repair Immunohistochemistry and Microsatellite Instability Testing. <i>American Journal of Surgical Pathology</i> , 2012, 36, 560-569.	3.7	23
53	HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis. <i>Histopathology</i> , 2012, 60, 547-553.	2.9	25
54	Nucleic acid quantity and quality from paraffin blocks: Defining optimal fixation, processing and DNA/RNA extraction techniques. <i>Experimental and Molecular Pathology</i> , 2012, 92, 33-43.	2.1	100

#	ARTICLE	IF	CITATIONS
55	Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. <i>Cancer</i> , 2012, 118, 681-688.	4.1	71
56	The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 239-252.	3.3	50
57	Histologic Artifacts in Abdominal, Vaginal, Laparoscopic, and Robotic Hysterectomy Specimens. <i>American Journal of Surgical Pathology</i> , 2011, 35, 115-126.	3.7	74
58	Biomarker Expression in Pelvic High-grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2011, 30, 366-371.	1.4	34
59	FOXL2 Is a Sensitive and Specific Marker for Sex Cord-Stromal Tumors of the Ovary. <i>American Journal of Surgical Pathology</i> , 2011, 35, 484-494.	3.7	183
60	In-Depth Proteomics of Ovarian Cancer Ascites: Combining Shotgun Proteomics and Selected Reaction Monitoring Mass Spectrometry. <i>Journal of Proteome Research</i> , 2011, 10, 2286-2299.	3.7	72
61	Calculator for ovarian carcinoma subtype prediction. <i>Modern Pathology</i> , 2011, 24, 512-521.	5.5	95
62	IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 2538-2548.	7.0	217
63	Claudin 4 Is Differentially Expressed between Ovarian Cancer Subtypes and Plays a Role in Spheroid Formation. <i>International Journal of Molecular Sciences</i> , 2011, 12, 1334-1358.	4.1	33
64	Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible. <i>American Journal of Surgical Pathology</i> , 2010, 34, 984-993.	3.7	143
65	Primary Ovarian Mucinous Carcinoma of Intestinal Type: Significance of Pattern of Invasion and Immunohistochemical Expression Profile in a Series of 31 Cases. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 99-107.	1.4	90
66	Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 203-211.	1.4	332
67	High-Grade Endometrial Carcinoma: Serous and Grade 3 Endometrioid Carcinomas Have Different Immunophenotypes and Outcomes. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 343-350.	1.4	146
68	Tumor type and substage predict survival in stage I and II ovarian carcinoma: Insights and implications. <i>Gynecologic Oncology</i> , 2010, 116, 50-56.	1.4	129
69	Functional Proteomic Analysis of Advanced Serous Ovarian Cancer Using Reverse Phase Protein Array: TGF- β 2 Pathway Signaling Indicates Response to Primary Chemotherapy. <i>Clinical Cancer Research</i> , 2010, 16, 2852-2860.	7.0	58
70	Nectin 4 Overexpression in Ovarian Cancer Tissues and Serum. <i>American Journal of Clinical Pathology</i> , 2010, 134, 835-845.	0.7	152
71	<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas. <i>New England Journal of Medicine</i> , 2010, 363, 1532-1543.	27.0	1,460
72	S100A1 Expression in Ovarian and Endometrial Endometrioid Carcinomas Is a Prognostic Indicator of Relapse-Free Survival. <i>American Journal of Clinical Pathology</i> , 2009, 132, 846-856.	0.7	42

#	ARTICLE	IF	CITATIONS
73	Regulation of HSulf-1 Expression by Variant Hepatic Nuclear Factor 1 in Ovarian Cancer. <i>Cancer Research</i> , 2009, 69, 4843-4850.	0.9	40
74	Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. <i>Modern Pathology</i> , 2009, 22, 393-402.	5.5	241
75	IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. <i>Modern Pathology</i> , 2009, 22, 469-475.	5.5	125
76	Mutation of <i>FOXL2</i> in Granulosa-Cell Tumors of the Ovary. <i>New England Journal of Medicine</i> , 2009, 360, 2719-2729.	27.0	706
77	A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary. <i>American Journal of Surgical Pathology</i> , 2009, 33, 14-21.	3.7	211
78	Amplification of 11q13 in ovarian carcinoma. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 481-489.	2.8	116
79	The prognostic significance of elongation factor eEF1A2 in ovarian cancer. <i>Gynecologic Oncology</i> , 2008, 108, 561-568.	1.4	47
80	Expression of Class I Histone Deacetylases Indicates Poor Prognosis in Endometrioid Subtypes of Ovarian and Endometrial Carcinomas. <i>Neoplasia</i> , 2008, 10, 1021-1027.	5.3	158
81	Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. <i>Human Pathology</i> , 2008, 39, 1239-1251.	2.0	231
82	Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies. <i>PLoS Medicine</i> , 2008, 5, e232.	8.4	675
83	Amplification of <i>PVT1</i> Contributes to the Pathophysiology of Ovarian and Breast Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 5745-5755.	7.0	345
84	Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. <i>BMC Medicine</i> , 2007, 5, 33.	5.5	52
85	Tomographic Comparison of Ventilation Techniques for CT-Guided Thoracoscopic Staple Excision of Subcentimeter Lung Nodules. <i>Journal of Investigative Surgery</i> , 2006, 19, 185-191.	1.3	1
86	CT-Directed Microcoil Localization of Small Peripheral Lung Nodules: A Feasibility Study in Pigs. <i>Journal of Investigative Surgery</i> , 2005, 18, 265-272.	1.3	16
87	Detection of Lung Perfusion Abnormalities Using Computed Tomography in a Porcine Model of Pulmonary Embolism. <i>Journal of Thoracic Imaging</i> , 2003, 18, 14-20.	1.5	43